Hengrui Pharma(SH:600276) Xin Lang Ji Jin·2025-08-21 12:13Group 1 - The A-share pharmaceutical sector showed strong performance, with the only ETF tracking the pharmaceutical index (562050) reaching a record closing price of 1.108 yuan, up 1.45% [1] - Major pharmaceutical companies like Heng Rui Medicine and Bai Jie Shen Zhou reported significant gains, with Heng Rui Medicine up 1.81% and Bai Jie Shen Zhou up 2.42% [1] - The overall market sentiment was positive, with 18 out of 50 companies in the ETF having disclosed their mid-year results, and 12 of those showing positive net profit growth [3] Group 2 - Heng Rui Medicine's mid-year report indicated a revenue of 15.76 billion yuan, a year-on-year increase of 15.9%, and a net profit of 4.45 billion yuan, up 29.7% [3] - Bai Jie Shen Zhou exceeded expectations with a projected revenue growth of 46% and a net profit increase of 115.63% [3] - Notable performers included Da Ren Tang with a net profit growth of 193% and Gan Li Pharmaceutical with a doubling of net profit [4] Group 3 - High-level discussions emphasized the need for increased support for the biopharmaceutical industry, focusing on high-quality technological supply and policy support [5] - The strategy includes promoting the modernization and industrialization of traditional Chinese medicine through innovation [5] - Investors are encouraged to consider the pharmaceutical ETF (562050) and its associated funds, which focus on leading pharmaceutical companies and innovative drugs [5]